Japanese encephalitis is a viral infection that spreads by mosquito bites. The study analyzed that the Japanese encephalitis therapeutics pipeline comprises approximately 12 drug candidates in different stages of development.
Shandong Hengye Biotech Co., Ltd., and VABIOTECH, have one drug candidates each in the Phase III stage of development for the treatment of the disease. The clinical studies of the vaccine, Vero cell-derived inactivated, is currently going on in China in the Phase III stage of development for the treatment of Japanese encephalitis.
Explore Report Sample at: http://bit.ly/2BB9Qiw
The companies developing drugs for the treatment of Japanese encephalitis are laying more emphasis on the drug candidates to be developed as vaccines, due to the promising results shown by these candidates the in the clinical development. Based on molecule type, around 75.0% of the therapeutic candidates are being developed as vaccines, around 13.0% are made as peptide and 12.0% are being developed as small molecule.
In September 2017, VABIOTECH in collaboration with National Institute of Hygiene and Epidemiology (NIHE), Vietnam, initiated a Phase III, randomized, multi-centered, parallel groups assignment trial to assess the immunogenicity and safety of the JECEVAX in healthy male as well as female children of age between nine to 24 months.
Pre-Purchase Inquiry at: http://bit.ly/2DJ4Ji8
Some of the key players developing drugs for the treatment of Japanese encephalitis include Shandong Hengye Biotech, Co. Ltd., Panacea Biotec Ltd., and Ennaid Therapeutics, LLC.